High-performance liquid chromatographic analysis of clorazepate dipotassium and monopotassium in solid dosage forms.
Methodology for the quantitative determination of clorazepate dipotassium and monopotassium in solid dosage forms was developed. Clorazepate was resolved from its degradation products, making the analysis specific and stability indicating. Analytical separation was performed on a octadecylsilylated silica column. Clorazepate was extracted from the dosage forms with 0.04% NaOH and chromatographed with aqueous 0.005 M tetra-n-butylammonium ion (pH 7.5)- acetonitrile (70:30) as the eluent. The analysis was completed in approximately 20 min with a precision of less than 2.4% RSD.
D014151:Anti-Anxiety Agents / Q000032:analysis*; D002214:Capsules / Q000032:analysis; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003009:Clorazepate Dipotassium / Q000032:analysis*; D004355:Drug Stability; D013607:Tablets / Q000032:analysis
D014151:Anti-Anxiety Agents; D002214:Capsules; D013607:Tablets; D003009:Clorazepate Dipotassium